奥美拉唑联合奥曲肽治疗方案对肝硬化上消化道出血的临床疗效探究

The Clinical Effect of Omeprazole Combined with Octreotide Treatment Program on Upper Gastrointestinal Bleeding in Liver Cirrhosis

目的探究肝硬化上消化道出血患者运用奥美拉唑联合奥曲肽治疗方案的临床疗效。方法择选2019年1月—2020年1月该院收治的80例由肝硬化引发的上消化道出血患者为研究对象,由计算机系统随机分为两组,即研究组(40例,行奥美拉唑联合奥曲肽治疗)和对照组(40例,常规治疗方案),对比两组患者的临床疗效和相关指标变化情况。结果研究组临床疗效治疗有效率(97.5%)明显优于对照组的80.0%,差异有统计学意义(χ2=4.507,P<0.05);研究组患者治疗后的血清胰高血糖素为(165.4±27.8)pg/mL、NO浓度为(99.3±17.7)μmol/L,对照组血清胰高血糖素为(192.3±29.2)pg/mL、NO浓度为(119.3±18.2)μmol/L,差异有统计学意义(t=4.219、4.982,P<0.05)。结论给予肝硬化上消化道出血患者奥美拉唑联合奥曲肽治疗方案,有效提高其治疗效果,改善患者预后情况,具有较高的临床应用价值。

Objective To explore the clinical efficacy of omeprazole combined with octreotide in patients with upper gastrointestinal bleeding in liver cirrhosis.Methods From January 2019 to January 2020,80 patients with upper gastrointestinal bleeding caused by liver cirrhosis were selected as the research objects,and they were randomly divided into two groups by the computer system,namely the research group(40 cases,omeprazole combined with octreotide treatment)and the control group(40 cases,conventional treatment plan).After a period of treatment,the clinical efficacy and changes in related indicators of the two groups were compared.Results The clinical curative effect rate(97.5%)of the study group was significantly better than that of the control group 80.0%,the difference was statistically significant(χ2=4.507,P<0.05);the serum glucagon of the study group after treatment was(165.4±27.8)pg/mL,NO concentration was(99.3±17.7)μmol/L,control group serum glucagon was(192.3±29.2)pg/mL,NO concentration was(119.3±18.2)μmol/L,the difference was statistically significant(t=4.219,4.982,P<0.05).Conclusion The treatment of omeprazole combined with octreotide in patients with liver cirrhosis and upper gastrointestinal bleeding can effectively improve the treatment effect and improve the prognosis of patients.It has high clinical application value.